We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MFT:NZXMainfreight Limited Analysis

Data as of 2026-03-15 - not real-time

€1.83

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Matica Fintec trades around €1.83, well above its DCF‑derived fair value of roughly €0.65, indicating the stock is currently overvalued despite a modest P/E of ~9.6 versus an industry average of ~33.7. Technical indicators are neutral – the 20‑day SMA (≈1.85) sits just above price, RSI hovers near 47, and the MACD shows a tiny bullish histogram, while volume is on a downtrend and the price is squeezed between a support of ~€1.75 and resistance near €1.96. Fundamentally, revenue has slipped 3.8% YoY, margins remain respectable (gross ~67%), but free cash flow is negative and debt‑to‑equity sits around 33%, adding balance‑sheet pressure. The company operates in a highly regulated ID‑card market across many regions, exposing it to regulatory and geographic risks, yet its low beta (~0.12) suggests limited market‑wide volatility. Overall, the stock offers a value‑oriented price relative to peers but is priced above intrinsic estimates, with high volatility and liquidity concerns.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • DCF indicates significant overvaluation
  • High 30‑day volatility and decreasing volume
  • Price near short‑term resistance with limited upside

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Relative valuation appears cheap versus industry peers
  • Stable gross margins but revenue contraction persists
  • Balance‑sheet leverage and negative free cash flow remain concerns

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • Low beta reduces market‑wide risk exposure
  • Diversified geographic footprint offers growth avenues if contracts are secured
  • Potential upside if price aligns with intrinsic DCF valuation

Key Metrics & Analysis

Financial Health

Revenue Growth-3.80%
Profit Margin9.33%
P/E Ratio9.6
ROE12.11%
ROA6.20%
Debt/Equity32.91
P/B Ratio1.1
Op. Cash Flow€2.7M
Free Cash Flow€-154610
Industry P/E33.7

Technical Analysis

TrendNeutral
RSI47.0
Support€1.75
Resistance€1.96
MA 20€1.85
MA 50€1.86
MA 200€1.81
MACDBullish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair Value€0.65
Target Price€2.65
Upside/Downside44.81%
GradeOvervalued
TypeValue

Risk Assessment

Beta0.11
Volatility36.70%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.